Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
15
06
2021
received:
19
05
2021
accepted:
09
08
2021
pubmed:
29
8
2021
medline:
14
10
2021
entrez:
28
8
2021
Statut:
ppublish
Résumé
Increase in lipid levels associated with the treatment of inflammatory bowel disease (IBD) has previously been reported. However, it is unknown if this effect is similar for all IBD drug classes. To precisely assess the effect of different IBD drug classes on lipid profiles METHODS: We performed a systematic literature search of randomised controlled trials and observational cohort studies that assessed lipid levels before and after induction (≤10 weeks) and maintenance (>10 weeks) of IBD treatment. Data of 11 studies (1663 patients) were pooled using random effects models. The influence of patient and disease characteristics on treatment effects on total cholesterol levels was analysed in 6 studies (1211 patients) for which individual data were available, using linear mixed models. A statistically significant increase in total cholesterol was observed after induction treatment with corticosteroids (+1.19 mmol/L, 95% confidence interval [CI Increase in total cholesterol levels was strongest for corticosteroids followed by tofacitinib but was not observed for anti-TNFα agents. Whether total cholesterol change associated with IBD treatment has an effect on cardiovascular risk requires further study.
Sections du résumé
BACKGROUND
Increase in lipid levels associated with the treatment of inflammatory bowel disease (IBD) has previously been reported. However, it is unknown if this effect is similar for all IBD drug classes.
AIM
To precisely assess the effect of different IBD drug classes on lipid profiles METHODS: We performed a systematic literature search of randomised controlled trials and observational cohort studies that assessed lipid levels before and after induction (≤10 weeks) and maintenance (>10 weeks) of IBD treatment. Data of 11 studies (1663 patients) were pooled using random effects models. The influence of patient and disease characteristics on treatment effects on total cholesterol levels was analysed in 6 studies (1211 patients) for which individual data were available, using linear mixed models.
RESULTS
A statistically significant increase in total cholesterol was observed after induction treatment with corticosteroids (+1.19 mmol/L, 95% confidence interval [CI
CONCLUSIONS
Increase in total cholesterol levels was strongest for corticosteroids followed by tofacitinib but was not observed for anti-TNFα agents. Whether total cholesterol change associated with IBD treatment has an effect on cardiovascular risk requires further study.
Identifiants
pubmed: 34453860
doi: 10.1111/apt.16580
pmc: PMC9291119
doi:
Substances chimiques
Lipids
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1012Informations de copyright
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
J Crohns Colitis. 2014 Jun;8(6):469-79
pubmed: 24183231
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1607-1615.e1
pubmed: 29702298
Ann Gastroenterol. 2011;24(3):181-187
pubmed: 24713706
PLoS One. 2013;8(2):e56944
pubmed: 23457642
Aliment Pharmacol Ther. 2020 May;51(9):880-888
pubmed: 32237087
J Crohns Colitis. 2014 Sep;8(9):992-7
pubmed: 24530134
Clin Pharmacol Ther. 2008 Jan;83(1):70-6
pubmed: 17507924
Inflamm Bowel Dis. 2021 May 17;27(6):797-808
pubmed: 32870265
J Clin Lipidol. 2017 Sep - Oct;11(5):1243-1256
pubmed: 28751001
Nutr Metab Cardiovasc Dis. 2018 Nov;28(11):1100-1105
pubmed: 30143407
Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3
pubmed: 31077827
Cell Biochem Funct. 2009 Oct;27(7):407-16
pubmed: 19757404
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Crohns Colitis. 2020 Oct 5;14(10):1385-1393
pubmed: 32280965
Eur J Gastroenterol Hepatol. 2009 Mar;21(3):283-8
pubmed: 19279474
Circ Res. 2017 Jan 20;120(2):366-380
pubmed: 28104770
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Heart. 2016 Dec 15;102(24):1957-1962
pubmed: 27534979
Dig Dis Sci. 2015 Jul;60(7):2130-5
pubmed: 25680875
Aliment Pharmacol Ther. 2021 Oct;54(8):999-1012
pubmed: 34453860
Eur J Prev Cardiol. 2018 Oct;25(15):1623-1631
pubmed: 30074405
Int J Endocrinol. 2018 Mar 05;2018:6712901
pubmed: 29576769
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):e46-7
pubmed: 26852393
Ther Adv Chronic Dis. 2010 Jul;1(4):177-86
pubmed: 23251737
Gut. 2020 May;69(5):852-858
pubmed: 31446428
Semin Arthritis Rheum. 2016 Dec;46(3):261-271
pubmed: 27443588
Ann Rheum Dis. 2012 Jun;71(6):862-8
pubmed: 22267329
Arthritis Rheumatol. 2015 Mar;67(3):616-25
pubmed: 25470338
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Control Clin Trials. 2004 Feb;25(1):13-30
pubmed: 14980746
Nat Rev Rheumatol. 2013 Sep;9(9):513-23
pubmed: 23774906
Scand J Gastroenterol. 2014 Jan;49(1):59-65
pubmed: 24138131
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
J Crohns Colitis. 2019 Mar 26;13(3):319-323
pubmed: 30321330
Ann Intern Med. 1996 Oct 1;125(7):605-13
pubmed: 8815760
Arthritis Res Ther. 2016 Nov 10;18(1):261
pubmed: 27832797
Lancet. 2017 Jan 21;389(10066):266-275
pubmed: 27988142
J Gastroenterol Hepatol. 2019 Jun;34(6):1004-1010
pubmed: 30551266
Clin Exp Gastroenterol. 2020 Apr 24;13:107-113
pubmed: 32425576
Clin Gastroenterol Hepatol. 2012 Sep;10(9):1002-7; quiz e78
pubmed: 22343692
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395
pubmed: 31112005
Gut. 2013 May;62(5):689-94
pubmed: 22961677
N Engl J Med. 2012 Aug 16;367(7):616-24
pubmed: 22894574
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120